Miedzyleski Szpital Specjalistyczny W Warszawie
- Address
- Ul. Bursztynowa 2, 04-749 Warsaw, Poland
Miedzyleski Szpital Specjalistyczny W Warszawie - Nephrology and Neurology Research Center
Miedzyleski Szpital Specjalistyczny W Warszawie is a specialized medical research center with significant expertise in rare kidney diseases and neurological disorders. The center demonstrates advanced capabilities in conducting complex clinical trials involving novel therapeutic agents and biosimilar studies, with a particular focus on conditions requiring long-term monitoring and specialized care protocols.
- Immunoglobulin A Nephropathy (IgAN) - investigating novel dual-mechanism receptor blockers and endothelin receptor antagonists for proteinuria reduction and renal function preservation
- Focal Segmental Glomerulosclerosis (FSGS) - evaluating nephroprotective treatments for primary and genetic forms of this progressive kidney disease
- Relapsing-remitting Multiple Sclerosis - conducting biosimilar pharmacokinetic and pharmacodynamic studies for B-cell depleting therapies
The center's research portfolio emphasizes both rare glomerular diseases and autoimmune neurological conditions, with particular strength in evaluating innovative pharmacological interventions aimed at preserving organ function. Their participation in phase 3 studies and open-label extension trials demonstrates commitment to understanding both immediate efficacy and long-term safety profiles of emerging therapies. The center's expertise spans from proteinuria assessment and renal function monitoring to advanced neuroimaging endpoints in multiple sclerosis trials.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Eli Lilly & Co.1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Travere Therapeutics Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Miedzyleski Szpital Specjalistyczny W Warszawie
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in study participants with palmoplantar pustulosis | UCB Biopharma | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Irbesartan | 2 | Unknown | 2018-10-15 | 2019-02-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.